<?xml version="1.0" encoding="UTF-8"?>
<p>The current COVID‐19 pandemic might also pose a risk to pediatric patients with secondary immunodeficiencies, such as patients on immunosuppressive therapy for autoimmune or severe allergic diseases. It is recommended to continue the treatment, including immunosuppressants. In the case a secondary deficiency is treated by immunoglobulin substitution, continuation is recommended. The use of convalescent plasma might be considered in these cases in the future, when this now emerging COVID‐19 treatment option is scientifically established.
 <xref rid="pai13262-bib-0035" ref-type="ref">
  <sup>35</sup>
 </xref>
</p>
